Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimittri Delevry

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of the American Academy of Dermatology|December 28, 2025
Dupilumab treatment improves health-related quality of life in patients with moderate-to-severe atopic dermatitis primarily affecting the hands (atopic hand eczema): results from a randomized placebo-controlled trialEric L Simpson, Marie-Louise A Schuttelaar, Sonja Molin, et al.
Dermatology and Therapy|May 11, 2022
Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records DatasetLawrence F Eichenfield, April Armstrong, Emma Guttman-Yassky, et al.
Dermatology and Therapy|October 21, 2022
Development, Psychometric Validation and Responder Definition of Worst Itch Scale in Children with Severe Atopic DermatitisAmy S Paller, Gil Yosipovitch, Stephan Weidinger, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 4, 2025
Dupilumab improves quality of life assessed by the Quality of Life in Hand Eczema QuestionnaireEric L Simpson, Marie-Louise A Schuttelaar, Sonja Molin, et al.
Dermatology and Therapy|October 29, 2021
Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic DermatitisGil Yosipovitch, Marjolein de Bruin-Weller, April Armstrong, et al.
Dermatology and Therapy|August 8, 2023
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD StudyAlexa B Kimball, Dimittri Delevry, Min Yang, et al.
American Journal of Clinical Dermatology|May 14, 2022
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)Andrew Blauvelt, Emma Guttman-Yassky, Amy S Paller, et al.
The Journal of Pediatrics|May 1, 2022
The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-sectional StudySebastien Barbarot, Jonathan I Silverberg, Abhijit Gadkari, et al.
The British Journal of Dermatology|December 4, 2023
Burden of atopic dermatitis in paediatric patients: an international cross-sectional studyStephan Weidinger, Eric L Simpson, Jonathan I Silverberg, et al.
Journal of the American Academy of Dermatology|January 31, 2024
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trialEric L Simpson, Jonathan I Silverberg, Margitta Worm, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of the American Academy of Dermatology|December 28, 2025
Dupilumab treatment improves health-related quality of life in patients with moderate-to-severe atopic dermatitis primarily affecting the hands (atopic hand eczema): results from a randomized placebo-controlled trialEric L Simpson, Marie-Louise A Schuttelaar, Sonja Molin, et al.
Dermatology and Therapy|May 11, 2022
Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records DatasetLawrence F Eichenfield, April Armstrong, Emma Guttman-Yassky, et al.
Dermatology and Therapy|October 21, 2022
Development, Psychometric Validation and Responder Definition of Worst Itch Scale in Children with Severe Atopic DermatitisAmy S Paller, Gil Yosipovitch, Stephan Weidinger, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 4, 2025
Dupilumab improves quality of life assessed by the Quality of Life in Hand Eczema QuestionnaireEric L Simpson, Marie-Louise A Schuttelaar, Sonja Molin, et al.
Dermatology and Therapy|October 29, 2021
Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic DermatitisGil Yosipovitch, Marjolein de Bruin-Weller, April Armstrong, et al.
Dermatology and Therapy|August 8, 2023
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD StudyAlexa B Kimball, Dimittri Delevry, Min Yang, et al.
American Journal of Clinical Dermatology|May 14, 2022
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)Andrew Blauvelt, Emma Guttman-Yassky, Amy S Paller, et al.
The Journal of Pediatrics|May 1, 2022
The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-sectional StudySebastien Barbarot, Jonathan I Silverberg, Abhijit Gadkari, et al.
The British Journal of Dermatology|December 4, 2023
Burden of atopic dermatitis in paediatric patients: an international cross-sectional studyStephan Weidinger, Eric L Simpson, Jonathan I Silverberg, et al.
Journal of the American Academy of Dermatology|January 31, 2024
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trialEric L Simpson, Jonathan I Silverberg, Margitta Worm, et al.
Pageof 2